The UK and US have secured a key commercial pact that will maintain zero levies on UK pharmaceutical shipments entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to boost expenditure on drugs through the public health system. This commitment secures that import taxes on these key products will be held at zero for a period of the next three years.
This development comes after recent warnings to hike duties on patented drug products, with increases mentioned up to one hundred percent.
"This arrangement with the UK reinforces the worldwide climate for innovative medicines and introduces much-needed equity to American-British medicine commerce," an announcement noted.
Commercial Significance
Drugs are one of the the United Kingdom's biggest export categories to the US, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to last September, the UK exported drugs valued at over eleven billion pounds to the US. This amount represented a significant portion of British export trade in that span.
"This guarantee secures work, stimulates investment and facilitates the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific British Pledges
The pact entails several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall public funding on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The amount manufacturers must return to the NHS to control costs will be limited at 15%. In the past, rebates were more than twenty percent.
Broader Context
The deal follows a protracted dispute between the sector and the British authorities over spending levels and regulatory access.
This friction were intensified by assertions that US consumers were charged a premium for the identical medicines than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had declined as a share of its total funding over the past decade.
